
Loading, please wait...

Loading, please wait...

Scientists are revolutionizing bioactive peptide delivery through sophisticated nanotechnology. However, traditional oral applications often fail because of low gastrointestinal stability. Consequently, enzymes in the digestive tract degrade these beneficial molecules before they reach their target. Therefore, researchers developed a novel hybrid system using liposome-loaded electrospun fibers to safeguard these compounds.
Specifically, the study team encapsulated glutenin hydrolysate (GH) into lecithin-phytosterol liposomes with an average size of 76 nm. Furthermore, they successfully embedded these liposomes into pullulan and carboxymethylcellulose nanofibers. Moreover, the results demonstrated that this hybrid configuration significantly protected the GH during the harsh gastric phase. Additionally, the system preserved the antioxidant activity of the GH throughout the digestive process. Notably, co-axial fibers provided a more sustained intestinal release compared to uni-axial or free-GH fibers. Similarly, the incorporation of liposomes into the fiber matrix improved mucoadhesive properties. Thus, this food-grade strategy offers a promising solution for the oral delivery of bioactive peptides in functional foods.
Oral delivery faces hurdles like enzymatic degradation and low gastrointestinal stability, which reduce the absorption of health-promoting peptides. However, advanced encapsulation techniques can mitigate these risks effectively.
Co-axial fibers provide a core-sheath structure that allows for more sustained intestinal release. Consequently, they protect the bioactive load more effectively than conventional uni-axial fibers during gastric transit.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.
References
1. Kalintas Caglar N et al. Characterization, in vitro release, and antioxidant activity of glutenin hydrolysate encapsulated in liposome-loaded uni-axial and co-axial electrospun fibers. J Sci Food Agric. 2026 Mar 11. doi: 10.1002/jsfa.70570. PMID: 41813609.
2. McClements DJ. Advancing oral delivery of bioactive peptides using colloidal delivery systems. Food Research International. 2018;108:320-334.
3. Zhang L, et al. Electrospun nanofibers for the delivery of bioactive agents. Advanced Drug Delivery Reviews. 2022;185:114302.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Study explores a hybrid liposome-nanofiber system to enhance the stability and controlled release of bioactive glutenin hydrolysate in the GI tract....
5 months ago

Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today